Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production

• Autorzy: Smith D. D. , Tan X. , Tawfik O. , Milne G. , Stechschulte D.J. , Dileepan K.N.
• Języki publikacji: EN

Abstrakty

EN

The production of thromboxane A2 (TXA2) and prostacyclin (prostaglandin I2, PGI2) is known to be increased in patients with atherosclerosis. In this study, we evaluated the influence of gender on TXA2 and PGI2 production, and their association with the progression of atherosclerosis in apolipoprotein E-null (ApoE-/-) mice maintained on a high fat diet for 3 months. En face analyses of aortas showed marked increases in plaque formation in female ApoE-/- mice. Quantification of the hematoxylin/eosin (H&E) stained cross sections of the aortic arch revealed 3 to 4-fold higher plaque thickness in female ApoE-/- mice. Analyses of 24-hours urine samples for 11-dehydro TXB2 and 2, 3-dinor-6-keto PGF1alpha indicated that female ApoE-/- mice produce up to 15-fold more TXA2 and 50% less PGI2 than the age matched males. Interestingly, the serum cholesterol levels in ApoE-/- females were 20% lower than males on the high fat regimen. No gender-associated changes in the number of T lymphocytes, mast cells and macrophages were evident in the lesion areas of ApoE-/- mice. The results suggest that the markedly elevated TXA2 production and reduced PGI2 production are gender-related proatherogenic risk factors in female ApoE-/- mice.

Słowa kluczowe

EN

apolipoprotein E-null mice; atherosclerosis; cardiovascular disease; gender difference; thromboxane A2; prostaglandin I2; estrogen; high-fat diet; prostacyclin; mice; mouse

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2010
• Tom: 61
• Numer: 3
• Opis fizyczny: p.309-316,fig.,ref.

Twórcy

autor

Smith D. D.

• University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA

autor

Tan X.

autor

Tawfik O.

autor

Milne G.

autor

Stechschulte D.J.

autor

Dileepan K.N.

Bibliografia

• Davies MJ. Apoptosis in cardiovascular disease. Heart 1997; 77: 498-501.
• Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104: 503-516.
• Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
• Grainger DJ, Metcalfe JC. A pivotal role for TGF-beta in atherogenesis? Biol Rev Camb Philos Soc 1995; 70: 571-596.
• Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997; 95: 1542-1548.
• McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991; 303: 435-437.
• Rutqvist LE. Long-term toxicity of tamoxifen. Recent Results Cancer Res 1993; 127: 257-266.
• Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 1992; 305: 225-226.
• Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327-1332.
• The Writing Group of the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen /Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
• FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310:1065-1068.
• Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2 -dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
• Turk JR. Protocol for macroscopic sudan IV staining of arteries for fatty streaks. MU Vasc Cell Biol. http://exercisevascularcells.org/SOP_CoreB/54.htm: 2002; 1-2.
• Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-794.
• Hodgin JB, Maeda N. Minireview: Estrogen and mouse models of atherosclerosis. Endocrinology 2002; 143: 4495-4501.
• von Dehn G, von Dehn O, Volker W, et al. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 2001; 33: 110-114.
• Badimon L. Atherosclerosis and thrombosis: lessons from animal models. Thromb Haemost 2001; 86: 356-365.
• Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003; 108:3017-3023.
• Olszanecki R, Jawien J, Gajda M, et al. Effect of curcumin on atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2005; 46: 627-635.
• Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-1014.
• Ma Z, Choudhury A, Kang SA, Monestier M, Cohen PL, Eisenberg RA. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 2008; 127: 168-175.
• Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
• Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1095-1100.
• Maeda N, Johnson L, Kim S, Hagaman J, Friedman M, Reddick R. Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds. Atherosclerosis 2007; 195: 75-82.
• Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and protacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823-3826.
• Jawien J, Gajda M, Olszanecki R, Korbut R. BAY x 1005 attenuates atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2007; 58: 583-588.
• Jawien J, Gajda M, Wolkow P, Zuranska J, Olszanecki R, Korbut R. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008; 59: 633-639.
• Babaev VR, Ding L, Reese J, et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 2006; 113:108-117.
• Yan Q, Yang X, Cantone A, Giebisch G, Hebert S, Wang T. Female ROMK null mice manifest more severe Bartter II phenotype on renal function and higher PGE2 production. Am J Physiol Reg Integr Comp Phys 2008; 295: R997-R1004.
• Egan KM, Wang M, Lucitt MB, et al. Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-342.
• Dileepan KN, Johnston TP, Li Y, Tawfik O, Stechschulte DJ. Deranged aortic intima-media thickness, plasma triglycerides and granulopoiesis in SI/SId mice. Med Inflamm 2004; 13: 335-341.
• Bourassa P-AK, Milos PM, Baynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996; 93: 10022-10027.
• Villablanca A, Lubahn D, Shelby L, Lloyd K, Barthold S. Susceptibility to early atherosclerosis in male mice is mediated by estrogen receptor a. Arterioscler Thromb Vasc Biol 2004; 24: 1055-1061.
• Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 2004; 279: 45085-45092.
• Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111: 347-355.
• Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci USA 2003; 100: 2748-2753.
• Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003; 111: 357-362.
• Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
• Marsh MM, Walker VR, Curtiss LK, Banka CL. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lip Res 1999; 40: 893-900.
• Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to extradiol: critical role of aromatase. Proc Natl Acad Sci USA 2001; 98: 3589-3593.
• Li M, Kuo L, Stallone JN. Estrogen potentiates constrictor prostanoid function in female rat aorta by up regulation of cyclooxygenase-2 and thromboxane pathway expression. Am J Physiol Heart Circ Physiol 2008; 294: H2444-H2455.
• Marttunen MB, Pyrhonen S, Tiitinen AE, Viinikka LU, Ylikorkala O. Effect of antiestrogen regimen on prostacyclin and thromboxane A2 in postmenopausal patients with breast cancer: evidence of significance of hypertension, smoking or previous use of estrogen therapy. Prostaglandins 1996; 52: 317-326.
• VanderLaan PA, Reardon CA. Thematic review series: The immune system and atherogenesis. The unusual suspects: an overview of the minor leukocyte populations in atherosclerosis. J Lip Res 2005; 46: 829-838.
• Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
• Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nature Med 2007; 13: 719-724.
• Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson GK. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 1999; 145: 301-308.
• Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 2008; 59:(Suppl 9): 155-167.
• Kus K, Gajda M, Pyka-Fosciak G, et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60: 163-165.
• Dejeans N, Auclair S, Chauvet S, Milenkovic D, Mazur A. Transcriptomic analysis of aorta from a short- term high-fat diet fed mouse reveals changes in the expression of vessel structure genes. J Physiol Pharmacol 2009; 60: 37-45.
• Fata JE, Chaudhary V, Khokha R. Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod 2001; 65: 680-688.
• Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005; 102: 8309-8314.